BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion
19.2.2025 03:05:00 CET | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / February 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report on several major milestones for the next 90 days, including the registration of national-level patents, the completion of a human bioequivalence study for its lead Multiple Sclerosis (MS) treatment, and the development of its longevity and anti-aging product.
Global Patent Filings: Accelerating Commercial Pathways for BioNxt's Pipeline
BioNxt confirm that all national-level filings pursuant to the Patent Cooperation Treaty (PCT) are complete in key jurisdictions of interest, including the United States, Canada, Australia, Europe, and Japan. The Company's national-level filings are based on the positive international examination report issued by the European Patent Office (EPO) in Q3 2024 for the Company's comprehensive patent application for sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases, such as MS. The Company is working to accelerate the processing and registration of national-level patents with updates to be provided as they develop.
Securing nation-level patents in premier pharmaceutical markets around the globe is a central milestone for BioNxt and will serve as the foundation for commercial opportunities for the Company's pipeline of sublingual products targeting autoimmune diseases such as multiple sclerosis (MS), myasthenia gravis (MG), lupus nephritis (LN) and rheumatoid arthritis (RA).
Human Bioequivalence Study for Lead Multiple Sclerosis Product
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence to existing oral therapies, with plans underway to commence the first clinical trial in the next 90 days. The bioequivalence study is relatively short and scheduled for less than 30 days from start to finish.
Successful completion of the Company's sublingual Cladribine bioequivalence study is a major milestone for the Company and a proof-of-concept demonstration for BioNxt's lead product and its pipeline of sublingual products targeting autoimmune diseases.
Expansion into Longevity and Anti-Aging
In the next 90 days, BioNxt plans to enter the rapidly growing longevity and anti-aging sector, projected to reach $93-billion (U.S.) by 2027 (Statista). The company is advancing proprietary sublingual (thin-film) and oral (enteric-coated tablet) drug products with active pharmaceutical ingredients that show early-stage evidence of benefits such as slowing ovarian aging, extending fertility and promoting healthy aging. These innovative solutions are tailored to meet the growing demand for effective anti-aging therapies.
The Company's longevity and anti-aging programs represent a strategic and diversified investment in a large and rapidly growing global market. BioNxt looks forward to providing further details in the coming weeks.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange:BNXT, OTC Markets:BNXTF and trades in Germany under WKN:A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Caldwell Strengthens Life Sciences and Healthcare Practice with Addition of Dr. Christoph Themel as Partner3.2.2026 11:30:00 CET | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / February 3, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Dr. Christoph Themel as a Partner in the firm's Life Sciences and Healthcare Practice. Based in London, Dr. Themel advises boards, investors, and senior leadership teams on executive and non-executive appointments, leadership assessments, and succession planning across the pharmaceutical, biotechnology, and animal health sectors. Dr. Christoph Themel joins Caldwell as partner in the firm's Life Sciences and Healthcare Practice With more than 20 years of experience in executive search and leadership advisory, Dr. Themel is a trusted advisor to big and mid-sized pharmaceutical companies, family-owned enterprises, private equity firms, and portfolio company leadership teams across Europe, the United States, and Asia Pacific. He is particularly known for his ability to partner closely with shareholders and management teams on C-sui
AI Rises on the Finance Leadership Agenda as Cost Control Dominates 2026, New Survey Reveals3.2.2026 10:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / February 3, 2026 / AccessPay, the leading bank integration provider, today announced the release of its Finance Trends 2026 report, presenting the findings of its annual survey of finance leaders. In this fourth year of the report, AccessPay reveals marked sectoral differences between finance teams in financial services firms and those in corporates with regards to their priorities and attitudes to technology adoption. Key findings from the report include: 1. Finance leaders are prioritising finance efficiency and cost control Finance teams across all sectors are placing renewed emphasis on efficiency and cost control in 2026. 47% of general corporates cited this as a priority, a goal shared by 46% of financial services firms. Although cost control is a perennial concern in financial management, sluggish economic growth, rising costs, and geopolitical turmoil have brought it to the fore. Finance leaders are being pushed to do more with less, which als
Formerra and Evonik Expand Distribution Partnership for Healthcare Grades2.2.2026 15:00:00 CET | Press release
Agreement Expands Access to Evonik's CARE Brand Medical Grades in the U.S. and Canada ROMEOVILLE, ILLINOIS / ACCESS Newswire / February 2, 2026 / Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications. This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup. With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgi
Hans Vestberg, Former Verizon Chairman and CEO, Joins Digipower X As Senior Advisor2.2.2026 13:30:00 CET | Press release
This news release constitutes a "designated news release" for the purposes of the Company's amended and restated prospectus supplement dated November 18, 2025, to its short form base shelf prospectus dated May 15, 2025. MIAMI, FL / ACCESS Newswire / February 2, 2026 / Digi Power X Inc. ("Digipower X" or the "Company") (Nasdaq:DGXX)(TSXV:DGX), a vertically integrated AI infrastructure company focused on the deployment of Tier-3 modular data centers powered by owned and controlled energy assets, today announced that Hans Vestberg, former Chairman and Chief Executive Officer of Verizon Communications, has joined the Company as a senior advisor serving on its Advisory Board to support the Company's expansion strategy. Mr. Vestberg brings more than three decades of global leadership in mission-critical infrastructure, telecommunications networks, and large-scale capital deployment. He is widely recognized for leading Verizon's first commercial 5G deployment in 2018 and for advancing nationw
Formerra to Supply Foster Medical Compounds in Europe29.1.2026 15:00:00 CET | Press release
Expanded agreement infuses Formerra's European healthcare polymer portfolio with life-saving Foster® compounds. PUTNAM, CT AND ROMEOVILLE, IL / ACCESS Newswire / January 29, 2026 / Formerra and GEON® Performance Solutions today announced an agreement that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in Europe. This adds to Formerra's current distribution of these materials in North and South America, enabling Formerra to now support customers who need the same product in all regions. Following GEON's January 2025 acquisition of Foster, the agreement builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "Bringing Foster's medical-grade portfolio to Europe strengthens our ability to support healthcare manufacturers across the region with specialized compounds and the local expertise they need to navigate complex regulatory environments," said Kelly Wessner, Vice President, Key
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom